Development of expression-based biomarkers of Dasatinib response in hematologic malignancies. [electronic resource]
- Blood cancer journal 12 2017
- 652 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't
2044-5385
10.1038/s41408-017-0013-z doi
Algorithms Antineoplastic Agents--therapeutic use Biomarkers, Tumor--analysis Dasatinib--therapeutic use Drug Resistance, Neoplasm--genetics Gene Expression Profiling--methods Hematologic Neoplasms--drug therapy Humans Treatment Outcome